Mechanism of action<unk>  is a fully humanized monoclonal antibody directed against calcitonin gene-related peptides (CGRP) alpha and beta. The precise mechanism of action is unknown. It is the only approved anti-CGRP monoclonal antibody that can be given with a quarterly interval. Pharmacokinetics After subcutaneous injection,<unk>  has a bioavailability of 55–66%. Highest concentrations in the body are reached after five to seven days. Like other proteins, the substance is degraded by proteolysis to small peptides and amino acids, which are reused or excreted via the kidney. The elimination half-life is estimated to be 30 to 31 days.
Fremanezumab
Ustekinumab
Tralokinumab
Olaratumab
Evolocumab
Bezlotoxumab
Alirocumab
Durvalumab